연구동향 분석

Development of Micelle-encapsulated ESIONs as a T1 Contrast Imaging Agent : Prolonged Blood Circulation and Enhanced Hepatobiliary Excretion

서민석 2020년

논문상세정보
인용/피인용
' Development of Micelle-encapsulated ESIONs as a T1 Contrast Imaging Agent : Prolonged Blood Circulation and Enhanced Hepatobiliary Excretion' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 의료과학 약
  • 64Cu-ESIONs
  • ESIONs
  • IONPs
  • PET/MRI
  • Pharmacokinetics
  • bio-distribution
  • 산화철나노입자
  • 양전자단층촬영
  • 자기공명 영상
  • 초소형 산화철 나노 입자
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
572 0

0.0%

' Development of Micelle-encapsulated ESIONs as a T1 Contrast Imaging Agent : Prolonged Blood Circulation and Enhanced Hepatobiliary Excretion' 의 참고문헌

  • cRGD-functionalized , DOX-conjugated , and ( 6 ) ( 4 ) Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging
    32 ( 17 ) :4151-60 . [2011]
  • Yousefi Babadi V. In vitro toxicity of iron oxide nanoparticle : oxidative damages on Hep G2 cells
    67 ( 2 ) :197-203 . [2015]
  • Xiao K. Uptake , distribution , clearance , and toxicity of iron oxide nanoparticles with different sizes and coatings
    8 ( 1 ) :2082 [2018]
  • Weller H. A highly effective , nontoxic T1 MR contrast agent based on ultrasmall PEGylated iron oxide nanoparticles
    9 ( 12 ) :4434-40 . [2009]
  • Ultrasmall superparamagnetic iron oxide : an intravenous contrast agent for assessing lymph nodes with MR imaging
    175 ( 2 ) :494-8 . [1990]
  • Ultra-large-scale syntheses of monodisperse nanocrystals
    3 ( 12 ) :891-5 . [2004]
  • Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging
    34 ( 1 ) :23-38 . [2006]
  • Translational radionanomedicine : a clinical perspective
    8 ( 2 ) :71-84 . [2016]
  • Trahms L. Magnetorelaxometry for localization and quantification of magnetic nanoparticles for thermal ablation studies .
    55 ( 3 ) :623-33 . [2010]
  • Toxicity assessment of silica coated iron oxide nanoparticles and biocompatibility improvement by surface engineering
    9 ( 1 ) : e85835 . [2014]
  • Toxicity , toxicokinetics and biodistribution of dextran stabilized Iron oxide Nanoparticles for biomedical applications
    511 ( 1 ) :586-98 . [2016]
  • Toward absolute quantification of iron oxide nanoparticles as well as cell internalized fraction using multiparametric MRI .
    7 ( 4 ) :411-7 . [2012]
  • The role of complement in inflammation and phagocytosis
    12 ( 9 ) :322-6 . [1991]
  • The blockade of immune checkpoints in cancer immunotherapy
    12 ( 4 ) :252-64 . [2012]
  • Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images : relationship with increasing cumulative dose of a gadolinium-based contrast material
    270 ( 3 ) :834-41 . [2014]
  • Surfactant-assisted synthesis of water-soluble and biocompatible semiconductor quantum dot micelles .
    5 ( 4 ) :645-8 . [2005]
  • Surface modification of iron oxide nanoparticles by biocompatible polymers for tissue imaging and targeting
    31 ( 8 ) :1224-36 . [2013]
  • Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles .
    31 ( 21 ) :5564-74 . [2010]
  • Superparamagnetic iron-oxide nanoparticles mPEG350and mPEG2000-coated : cell uptake and biocompatibility evaluation .
    12 ( 4 ) :909-19 . [2016]
  • Superparamagnetic iron oxide nanoparticles as a liver MRI contrast agent : contribution of microencapsulation to improved biodistribution
    7 ( 6 ) :619-27 . [1989]
  • Superparamagnetic iron oxide nanoparticles as MRI contrast agents for non-invasive stem cell labeling and tracking
    3 ( 8 ) :595-615 . [2013]
  • Superparamagnetic iron oxide contrast agents : physicochemical characteristics and applications in MR imaging
    11 ( 11 ) :2319-31 [2001]
  • Superparamagnetic iron oxide based MRI contrast agents : Current status of clinical application
    1 ( 1 ) :35-40 . [2011]
  • Superparamagnetic iron oxide : pharmacokinetics and toxicity
    152 ( 1 ) :167-73 . [1989]
  • Simultaneous Multiparametric PET/MRI with Silicon Photomultiplier PET and Ultra-High-Field MRI for Small-Animal Imaging .
    57 ( 8 ) :1309- 15 . [2016]
  • SimPET : a Preclinical PET Insert for Simultaneous PET/MR Imaging .
    [2020]
  • Shegokar R. Polyethylene glycol ( PEG ) : a versatile polymer for pharmaceutical applications .
    13 ( 9 ) :1257-75 . [2016]
  • Sen T. Superparamagnetic iron oxide nanoparticles ( SPIONs ) : development , surface modification and applications inChemotherapy .
    63 ( 1-2 ) :24-46 . [2011]
  • Selfassembly of ordered , robust , three-dimensional gold nanocrystal/silica arrays
    304 ( 5670 ) :567-71 . [2004]
  • Safety and tolerability of ultrasmall superparamagnetic iron oxideContrast agent :Comprehensive analysis of aClinical development program
    44 ( 6 ) :336-42 . [2009]
  • Safety and efficacy of rapidly administered ( one hour ) one gram of low molecular weight iron dextran ( INFeD ) for the treatment of iron deficient anemia
    86 ( 10 ) :860-2 . [2011]
  • Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysisChains in the United States over a 12-month period
    36 ( 1 ) :70-83 . [2014]
  • Revel D. Ultrasmall superparamagnetic iron oxide particles ( AMI 227 ) as a blood poolContrast agent for MR angiography : experimental study in rabbits
    7 ( 6 ) :958-62 . [1997]
  • RenalClearance of quantum dots
    25 ( 10 ) :1165-70 . [2007]
  • Real-time visualization ofClustering and intracellular transport of gold nanoparticles byCorrelative imaging
    8:15646 [2017]
  • Rapid Hepatobiliary Excretion of Micelle-Encapsulated/Radiolabeled Upconverting Nanoparticles as an Integrated Form
    5:15685 [2015]
  • Radionanomedicine
    [2018]
  • R. Influence of surfaceCharge density on protein adsorption on polymeric nanoparticles : analysis by twodimensional electrophoresis
    54 ( 2 ) :165-70 [2002]
  • Quantitative in vivoCellsurface receptor imaging in oncology : kinetic modeling and paired-agent principles from nuclear medicine and optical imaging
    60 ( 14 ) : R239-69 [2015]
  • Quantification of gadoliniumConcentration using GRE and UTE sequences
    21 ( 3 ) :171-6 . [2017]
  • Quantification and biodistribution of iron oxide nanoparticles in the primaryClearance organs of mice using T1Contrast for heating
    78 ( 2 ) :702-12 . [2017]
  • Pulmonary MR angiography with ultrasmall superparamagnetic iron oxide particles as a blood pool agent and a navigator echo for respiratory gating : pilot study
    211 ( 3 ) :865-9 . [1999]
  • Pseudolayering of Gd-DTPA in the urinary bladder
    174 ( 2 ) :379-81 . [1990]
  • Preclinical safety and pharmacokinetic profile of ferumoxtran-10 , an ultrasmall superparamagnetic iron oxide magnetic resonanceContrast agent
    41 ( 3 ) :313-24 . [2006]
  • Port M. Recent advances in iron oxide nanocrystal technology for medical imaging
    58 ( 14 ) :1471-504 . [2006]
  • Polymeric liposomes-coated superparamagnetic iron oxide nanoparticles asContrast agent for targeted magnetic resonance imaging ofCancerCells
    27 ( 6 ) :3100-5 . [2011]
  • Plasma stability and pharmacokinetics of radiolabeled deferoxamine-biotin derivatives .
    265 ( 1 ) :408-15 . [1993]
  • Petri-Fink A. Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles
    112 ( 4 ) :2323-38 [2012]
  • Parameters influencing the stealthiness of colloidal drug delivery systems
    27 ( 24 ) :4356-73 . [2006]
  • Pansu B. Solvent-driven interactions between hydrophobically-coated nanoparticles
    11 ( 19 ) :3920-6 . [2015]
  • PET/NIRF/MRI triple functional iron oxide nanoparticles
    31 ( 11 ) :3016-22 . [2010]
  • PET/MRI Hybrid Systems
    48 ( 4 ) :332-47 . [2018]
  • Nanoparticles modified by encapsulation of ligands with a long alkyl chain to affect multispecific and multimodal imaging
    53 ( 9 ) :1462-70 . [2012]
  • Nanoparticle-liver interactions : Cellular uptake and hepatobiliary elimination
    240:332-48 [2016]
  • Nanoparticle interactions with immune cells dominate tumor retention and induce T cell-mediated tumor suppression in models of breast cancer
    6 ( 13 ) : eaay1601 . [2020]
  • Multifunctional polymeric micelles as cancer-targeted , MRI-ultrasensitive drug delivery systems
    6 ( 11 ) :2427-30 . [2006]
  • Modeling receptor-mediated endocytosis of polymer-functionalized iron oxide nanoparticles by human macrophages
    32 ( 2 ) :547-55 . [2011]
  • Mitragotri S. A Review of Clinical Translation of Inorganic Nanoparticles
    17 ( 5 ) :1041-54 . [2015]
  • Materials advances through aberration-corrected electron microscopy
    31 ( 1 ) :36-43 . [2006]
  • Maity D. Recent advances in superparamagnetic iron oxide nanoparticles ( SPIONs ) for in vitro and in vivo cancer nanotheranostics
    496 ( 2 ) :191-218 . [2015]
  • Mahesh M. Retention Concerns About MR Studies Using Gadolinium-Based Contrast Agents
    15 ( 6 ) :934-6 . [2018]
  • Magnetosomelike ferrimagnetic iron oxide nanocubes for highly sensitive MRI of single cells and transplanted pancreatic islets .
    108 ( 7 ) :2662-7 . [2011]
  • Magnetoliposomes for controlled drug release in the presence of low-frequency magnetic field
    6 ( 1 ) :154-62 . [2010]
  • Magnetic targeting of magnetoliposomes to solid tumors with MR imaging monitoring in mice : feasibility .
    239 ( 2 ) :415-24 . [2006]
  • Magnetic resonance imaging diagnosis of metastatic lymph nodes in a rabbit model : efficacy of PJY10 , a new ultrasmall superparamagnetic iron oxide agent , with monodisperse iron oxide core and multiple-interaction ligands
    9 ( 9 ) : e107583 . [2014]
  • Magnetic particle imaging : kinetics of the intravascular signal in vivo
    9:4203-9 [2014]
  • Magnetic nanoparticle biodistribution following intratumoral administration
    22 ( 34 ) :345101 . [2011]
  • Magnetic iron oxide nanoparticles as T 1 contrast agents for magnetic resonance imaging
    6 ( 6 ) :1280-90 . [2018]
  • Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging
    39 ( 10 ) :619-25 [2004]
  • MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent .
    7 ( 1 ) :209-14 . [1997]
  • Lysosomal degradation of the carboxydextran shell of coated superparamagnetic iron oxide nanoparticles and the fate of professional phagocytes
    31 ( 34 ) :9015-22 . [2010]
  • Long term in vivo biotransformation of iron oxide nanoparticles
    32 ( 16 ) :3988-99 . [2011]
  • Li Y. pH-Dependent aggregation and pHindependent cell membrane adhesion of monolayer-protected mixed charged gold nanoparticles
    11 ( 15 ) :7371-85 . [2019]
  • Large-scale synthesis of uniform and extremely small-sized iron oxide nanoparticles for highresolution T1 magnetic resonance imaging contrast agents
    133 ( 32 ) :12624-31 . [2011]
  • Kinetics and pathogenesis of intracellular magnetic nanoparticle cytotoxicity .
    7901 [2011]
  • Kanal E. A serial dilution study of gadolinium-based MR imaging contrast agents
    29 ( 4 ) :668-73 . [2008]
  • Josephson L. Ultrasmall superparamagnetic iron oxide : characterization of a new class of contrast agents for MR imaging
    175 ( 2 ) :489-93 . [1990]
  • Iron oxide nanoparticles induce human microvascular endothelial cell permeability through reactive oxygen species production and microtubule remodeling
    0.250694444444444 [2009]
  • Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors
    29 ( 4 ) :487-96 . [2008]
  • Iron oxide nanoparticles : Diagnostic , therapeutic and theranostic applications
    138:302-25 [2019]
  • Iron oxide nanoclusters for T 1 magnetic resonance imaging of non-human primates
    1 ( 8 ) :637-43 . [2017]
  • Iron Oxide Nanoparticle Based Contrast Agents for Magnetic Resonance Imaging
    14 ( 5 ) :1352-64 [2017]
  • Intrinsically germanium-69-labeled iron oxide nanoparticles : synthesis and invivo dual-modality PET/MR imaging
    26 ( 30 ) :5119-23 . [2014]
  • Intracellular and extracellular T1 and T2 relaxivities of magneto-optical nanoparticles at experimental high fields .
    64 ( 6 ) :1607-15 . [2010]
  • Integrity of ( 111 ) In-radiolabeled superparamagnetic iron oxide nanoparticles in the mouse
    42 ( 1 ) :65-70 . [2015]
  • In vivo multimodal magnetic particle imaging ( MPI ) with tailored magneto/optical contrast agents
    52:251-61 [2015]
  • In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance
    41 ( 2 ) :329-33 . [1999]
  • In vivo integrity of polymer-coated gold nanoparticles
    10 ( 7 ) :619-23 . [2015]
  • In vivo delivery , pharmacokinetics , biodistribution and toxicity of iron oxide nanoparticles
    44 ( 23 ) :8576-607 [2015]
  • In vivo clearance and toxicity of monodisperse iron oxide nanocrystals
    6 ( 6 ) :4947-54 [2012]
  • In vivo applications of magnetic nanoparticle hyperthermia
    29 ( 8 ) :828-34 . [2013]
  • In Vivo Imaging of Quantum Dots Encapsulated in Phospholipid Micelles
    298 ( 5599 ) :1759-62 . [2002]
  • In Vivo Imaging and Quantification of Iron Oxide Nanoparticle Uptake and Biodistribution .
    8317 [2012]
  • In Vitro/In Vivo Toxicity Evaluation and Quantification of Iron Oxide Nanoparticles
    16 ( 10 ) :24417-50 . [2015]
  • Imaging Tumor Necrosis with Ferumoxytol .
    10 ( 11 ) : e0142665 . [2015]
  • If we build it they will come : targeting the immune response to breast cancer
    [2019]
  • Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages .
    26 ( 7 ) :1601-6 . [2006]
  • Hyeon T. Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents
    41 ( 7 ) :2575-89 . [2012]
  • Human serum albumin coated iron oxide nanoparticles for efficient cell labeling
    46 ( 3 ) :433-5 . [2010]
  • High-resolution cerebral blood volume imaging in humans using the blood pool contrast agent ferumoxytol
    70 ( 3 ) :705-10 . [2013]
  • Hepatic metabolism of colloidal goldlow-density lipoprotein complexes in the rat : evidence for bulk excretion of lysosomal contents into bile
    9 ( 3 ) :380-92 [1989]
  • Hepatic MR imaging with ferumoxides : a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions
    196 ( 2 ) :481-8 . [1995]
  • Gazeau F. Cell internalization of anionic maghemite nanoparticles : quantitative effect on magnetic resonance imaging
    49 ( 4 ) :646-54 . [2003]
  • Gao M. Facile synthesis of ultrasmall PEGylated iron oxide nanoparticles for dual-contrast T1- and T2-weighted magnetic resonance imaging
    22 ( 24 ) :245604 . [2011]
  • Ferumoxytol : in iron deficiency anaemia in adults with chronic kidney disease
    72 ( 15 ) :2013-22 . [2012]
  • Ferumoxytol : a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud ?
    3:77- 85 [2012]
  • Felix R. Inductive heating of ferrimagnetic particles and magnetic fluids : physical evaluation of their potential for hyperthermia
    9 ( 1 ) :51-68 . [1993]
  • Fast synthesis and bioconjugation of ( 68 ) Ga core-doped extremely small iron oxide nanoparticles for PET/MR imaging
    11 ( 3 ) :203-10 . [2016]
  • Fadeel B. Toxicology of engineered nanomaterials : focus on biocompatibility , biodistribution and biodegradation
    1810 ( 3 ) :361-73 . [2011]
  • Exceedingly small iron oxide nanoparticles as positive MRI contrast agents
    114 ( 9 ) :2325-30 . [2017]
  • Ex vivo MR imaging of atherosclerotic rabbit aorta labelled with USPIO— enhancement of iron loaded regions in UTE imaging .
    [2005]
  • Evaluation of a silicon photomultiplier PET insert for simultaneous PET and MR imaging
    43 ( 1 ) :72 . [2016]
  • Enhanced retention and cellular uptake of nanoparticles in tumors by controlling their aggregation behavior .
    7 ( 7 ) :6244-57 . [2013]
  • Effects of iron oxide nanoparticles : cytotoxicity , genotoxicity , developmental toxicity , and neurotoxicity
    56 ( 2 ) :125- 48 . [2015]
  • Effect of the intracellular localization of a Gd-based imaging probe on the relaxation enhancement of water protons
    55 ( 3 ) :491-7 . [2006]
  • Effect of PEG molecular weight on stability , T Contrast ,Cytotoxicity , andCellular uptake of superparamagnetic iron oxide nanoparticles ( SPIONs )
    [2014]
  • Effect of PEG molecular weight on stability , T ( 2 ) contrast , cytotoxicity , and cellular uptake of superparamagnetic iron oxide nanoparticles ( SPIONs )
    [2014]
  • Dubertret B. Synthesis , encapsulation , purification and coupling of single quantum dots in phospholipid micelles for their use in cellular and in vivo imaging
    2 ( 10 ) :2383-90 . [2007]
  • Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance
    30 ( 23-24 ) :3926-33 [2009]
  • Dextran and polymer polyethylene glycol ( PEG ) coating reduce both 5 and 30 nm iron oxide nanoparticle cytotoxicity in 2D and 3D cell culture
    13 ( 5 ) :5554-70 . [2012]
  • Development of a multimodal imaging probe by encapsulating iron oxide nanoparticles with functionalized amphiphiles for lymph node imaging
    10 ( 12 ) :1899-910 . [2015]
  • Detection of lymph node metastases with ultrasmall superparamagnetic iron oxide ( USPIO ) -enhanced magnetic resonance imaging in oesophageal cancer : a feasibility study .
    9:19-28 [2009]
  • Delie F. Nanoparticles for drug delivery : the need for precision in reporting particle size parameters
    69 ( 1 ) :1-9 [2008]
  • Dassler K. Studying the effect of particle size and coating type on the blood kinetics of superparamagnetic iron oxide nanoparticles
    7:4447-58 [2012]
  • Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress
    5:983-9 [2010]
  • Comparison of maximum signal intensity of contrast agent on t1-weighted images using spin echo , fast spin echo and inversion recovery sequences
    10 ( 1 ) :27-32 . [2012]
  • Comparison of electron spin resonance spectroscopy and inductively-coupled plasma optical emission spectroscopy for biodistribution analysis of iron-oxide nanoparticles .
    7 ( 2 ) :375-85 . [2010]
  • Cold Tumors : A Therapeutic Challenge for Immunotherapy .
    0.533333333 [2019]
  • Clearance Pathways and Tumor Targeting of Imaging Nanoparticles
    9 ( 7 ) :6655-74 . [2015]
  • Chemistry N. Biodistribution of ultra small superparamagnetic iron oxide nanoparticles in BALB mice
    295 ( 2 ) :1517-23 . [2013]
  • Certain types of iron oxide nanoparticles are not suited to passively target inflammatory cells that infiltrate the brain in response to stroke
    33 ( 5 ) : e1-9 . [2013]
  • Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
    25 ( 2 ) :268-76 . [2013]
  • Biodistribution and acute toxicity of a nanofluid containing manganese iron oxide nanoparticles produced by a mechanochemical process
    9:1919-29 [2014]
  • Alipour M. Investigating the cytotoxicity of iron oxide nanoparticles in in vivo and in vitro studies
    67 ( 10 ) :509-15 [2015]
  • Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging
    107 ( 19 ) :2453-8 . [2003]
  • A simple and widely applicable method to 59Fe-radiolabel monodisperse superparamagnetic iron oxide nanoparticles for in vivo quantification studies
    6 ( 8 ) :7318-25 . [2012]
  • A novel formulation for superparamagnetic iron oxide ( SPIO ) particles enhancing MR lymphography : comparison of physicochemical properties and the in vivo behaviour
    10 ( 3 ) :221-30 . [2002]
  • A model of lysosomal metabolism of dextran coated superparamagnetic iron oxide ( SPIO ) nanoparticles : implications for cellular magnetic resonance imaging
    18 ( 6 ) :383-9 . [2005]
  • A Review of Magnetic Particle Imaging and Perspectives on Neuroimaging
    40 ( 2 ) :206-12 . [2019]
  • 87. Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (London, England). 2010;5(4):523-8.
  • 40. Hagberg GE, Scheffler K. Effect of r(1) and r(2) relaxivity of gadoliniumbased contrast agents on the T(1)-weighted MR signal at increasing magnetic field strengths. Contrast Media Mol Imaging. 2013;8(6):456-65.
  • 27. Kanal E. Gadolinium based contrast agents (GBCA): Safety overview after 3 decades of clinical experience. Magn Reson Imaging. 2016;34(10):1341-5.
  • 25. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev. 2006;35(6):512-23.
  • 115. Zysler RD, Lima E, Jr., Vasquez Mansilla M, Troiani HE, Mojica Pisciotti ML, Gurman P, et al. A new quantitative method to determine the uptake of SPIONs in animal tissue and its application to determine the quantity of nanoparticles in the liver and lung of Balb-c mice exposed to the SPIONs. J Biomed Nanotechnol. 2013;9(1):142-5.
  • 110. Heine M, Bartelt A, Bruns OT, Bargheer D, Giemsa A, Freund B, et al. The cell-type specific uptake of polymer-coated or micelle-embedded QDs and SPIOs does not provoke an acute pro-inflammatory response in the liver. Beilstein J Nanotechnol. 2014;5:1432-40.
  • 1. Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med. 2010;363(25):2434-43.
    363 ( 25 ) :2434-43 . [2010]